Eisai Establishes Pharma Sales Subsidiary in Vietnam

Sep 17, 2020 09:59 JST

Source: Eisai

TOKYO, Sep 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam). Eisai Vietnam is a wholly-owned subsidiary of Eisai.

The pharmaceutical market in Vietnam is surpassed in size only by those of Thailand and the Philippines within the Association of Southeast Asian Nations (ASEAN), with the market size reaching 4,199 million USD in 20191. The compound annual growth rate of the Vietnamese pharmaceutical market from 2014 to 2019 was +10.6%(1), and it is expected that this market rate will continue to grow in the double digits. In 1992, Eisai (Thailand) Marketing Co., Ltd., a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency. Eisai opened a representative office in Ho Chi Minh City in 1995, and mainly markets the proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy treatment Methycobal, and others.

In addition, regarding its global products in Vietnam, Eisai recently launched its antiepileptic drug Fycompa in October 2019, and obtained marketing approval for the anti-cancer agent Lenvima in June 2020. Eisai has also filed for regulatory approval for the in-house developed anti-cancer agent Halaven.

With the establishment of Eisai Vietnam, Eisai aims to enhance its own drug sales system in Vietnam, deliver innovative new drugs to more patients in Vietnam, and contribute to improving the benefits of patients and their families.

(1) Copyright 2020 IQVIA Created based on IQVIA Analytics Link 2014-2019. Unauthorized reproduction prohibited.

Contact:

Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan

June 02 2025 16:46 JST

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China

May 28 2025 16:45 JST

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

May 21 2025 14:00 JST

Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro

May 16 2025 16:21 JST

Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star

April 30 2025 13:17 JST

Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

April 18 2025 15:52 JST

Eisai to Divest Rights for Pariet in China to Peak Pharma

April 01 2025 12:15 JST

World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards

March 25 2025 16:28 JST

Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace

March 25 2025 11:21 JST

Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time

March 10 2025 19:24 JST

More Press release >>

Latest Press Release

DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 04, 2025 16:20 JST

MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 04, 2025 15:13 JST

Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures
Jul 04, 2025 13:25 JST

Fujitsu to implement store monitoring solution for METRO Inc. in Canada, enhancing operational efficiency and policy compliance
Jul 04, 2025 13:19 JST

Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange
Jul 03, 2025 11:14 JST

Mitsubishi Motors Launches the All-New Grandis for the European Market
Jul 02, 2025 12:10 JST

Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability
Jul 02, 2025 12:00 JST

Fujitsu launches solution to enhance customers' global supply chain resilience
Jul 02, 2025 11:32 JST

MHI Receives Order to Supply Four Circulating Water Pumps for Units 5 and 6 of Sanmen Nuclear Power Plant in China Under Collaboration with Dongfang Electric Machinery
Jul 02, 2025 11:30 JST

Multi-purpose Arena in Odaiba Aomi Area TOYOTA ARENA TOKYO Construction Completed
Jul 01, 2025 22:56 JST

1Finity, a Fujitsu company, commences operations and reveals brand identity
Jul 01, 2025 22:53 JST

MHI Thermal Systems Begins Field Test of Jointly Developed "Surplus Renewable Energy Absorption and Release System"
Jul 01, 2025 22:40 JST

Japan's Telecommunications Carriers Strengthen Disaster Response Through Collaborative Information Sharing
Jul 01, 2025 22:30 JST

JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers
Jul 01, 2025 16:00 JST

Fujitsu provides Japan's first AI-powered cloud-based library search service
Jul 01, 2025 11:30 JST

JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 01, 2025 11:15 JST

First Shipment of LNG from the LNG Canada Project
Jul 01, 2025 11:00 JST

Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST

Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST

Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST

More Latest Release >>